Clinical Laserthermia Systems (CLS) Q1 2025 earnings summary

Executive summary

• Net sales increased 43% year-over-year to SEK 4.5 million for Q1 2025, driven by growth in the neurosurgery segment.

• Operating loss improved to SEK -7.9 million from SEK -17.0 million in Q1 2024, reflecting higher revenue, better gross margin, and reduced operating expenses.

• Profit/loss after financial items was SEK -15.2 million, compared to SEK -12.4 million in Q1 2024.

• Basic and diluted EPS improved to SEK -0.68 from SEK -1.89 year-over-year.

• Equity ratio strengthened to 88% from 81% at March 31, 2024.

Financial highlights

• Net sales: SEK 4,496,000 (Q1 2025) vs SEK 3,140,000 (Q1 2024).

• Operating profit: SEK -7,868,000 (Q1 2025) vs SEK -16,992,000 (Q1 2024).

• Profit/loss after financial items: SEK -15,230,000 (Q1 2025) vs SEK -12,397,000 (Q1 2024).

• Cash flow from operating activities: SEK -9,224,000 (Q1 2025) vs SEK -20,527,000 (Q1 2024).

• Cash and cash equivalents at period end: SEK 27,870,000 (March 31, 2025).

Outlook and guidance

• Focus on accelerating commercialization in neurosurgery through partnership with ClearPoint Neuro.

• Targeting positive cash flow by end of 2026, with continued cost-cutting and operational streamlining.

• Mid-term ambition to expand commercial partnerships beyond neurosurgery.